公开(公告)号：US09974763B2

公开(公告)日：2018-05-22

申请号：US14894621

申请日：2014-05-28

Applicant: B & A THERAPEUTICS ,  CENTRE HOSPITALIER UNIVERSITAIRE DE NANTES ,  INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE) ,  UNIVERSITE D'AIX-MARSEILLE ,  UNIVERSITE DE NANTES

Inventor： Yehezkel Ben-Ari ,  Nathalie Dehorter ,  Philippe Damier ,  Constance Hammond

IPC: A61K31/196 ,  A61K45/06 ,  C12N15/113 ,  A61K31/192

CPC classification number: A61K31/196 ,  A61K31/192 ,  A61K45/06 ,  C12N15/1138 ,  A61K2300/00

Abstract: A composition for treating Neurodegenerative Diseases with Parkinsonian Syndromes in a subject in need thereof, wherein the composition includes an effective amount of a modulator of a chloride transporter.

公开(公告)号：US09944699B2

公开(公告)日：2018-04-17

申请号：US14757529

申请日：2014-06-27

Applicant: GALDERMA RESEARCH & DEVELOPMENT ,  CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE ,  UNIVERSITE D'AIX-MARSEILLE

Inventor： Marcel Crest ,  Patrick Delmas ,  Aurélie Lonigro-Rame ,  Nancy Osorio

IPC: C07K16/28 ,  C12N15/113 ,  G01N33/50 ,  A61K39/00

CPC classification number: C07K16/28 ,  A61K2039/505 ,  C07K2317/24 ,  C07K2317/54 ,  C07K2317/55 ,  C07K2317/569 ,  C07K2317/622 ,  C07K2317/76 ,  C12N15/113 ,  C12N2310/11 ,  C12N2310/14 ,  C12N2310/141 ,  G01N33/5023

Abstract: The use of a modulator of the Nav 1.9 sodium channel is described for treating an inflammatory skin disease. Also described, is a pharmaceutical composition including a modulator of the Nav 1.9 sodium channel, and in vitro diagnostic methods based on the detection or quantification of Nav 1.9.

公开(公告)号：US09884088B2

公开(公告)日：2018-02-06

申请号：US14787483

申请日：2014-05-06

Applicant: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE ,  UNIVERSITE D'AIX-MARSEILLE

Inventor： Aziz Moqrich ,  Marie-Claire Delfini ,  Annabelle Mantilleri

IPC: A61K38/00 ,  A61P23/00 ,  A61K38/17 ,  A01K67/027 ,  C07K14/47

CPC classification number: A61K38/1709 ,  A01K67/0276 ,  A01K2217/077 ,  A01K2227/105 ,  A01K2267/0356 ,  C07K14/47

Abstract: The present invention relates to a method of using a TAFA4 protein or an agonist thereof for preventing, alleviating or treating pain in a subject. In one embodiment, the invention provides a method of treating pain in a subject by administering a TAFA4 protein or an agonist thereof to the subject. The TAFA4 can have the amino acid sequence of SEQ ID NO: 1 or 2 or a sequence having at least 90% sequence identity to SEQ ID NO: 1 or 2. The TAFA4 agonist can also be a peptide comprising 10 to 60 consecutive amino acid residues of SEQ ID NO: 1 or 2. Also described herein are pharmaceutical compositions, their preparation and uses as well as methods for preventing, alleviating or treating pain using such compounds and compositions.

公开(公告)号：US09861274B2

公开(公告)日：2018-01-09

申请号：US14912452

申请日：2014-08-07

Applicant: ESSILOR INTERNATIONAL (COMPAGNIE GENERALE D'OPTIQUE) ,  CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE—CNRS ,  UNIVERSITE D'AIX-MARSEILLE

Inventor： Carlos Aguilar ,  Eric Castet

IPC: A61B3/00 ,  A61B3/10 ,  G06T3/40 ,  G06T7/00 ,  G09B21/00

CPC classification number: A61B3/0025 ,  A61B3/0041 ,  A61B3/0091 ,  A61B3/10 ,  G06T3/40 ,  G06T7/0051 ,  G06T7/0081 ,  G06T7/11 ,  G06T7/50 ,  G06T2207/20112 ,  G06T2207/20144 ,  G06T2207/30201 ,  G09B21/008

Abstract: A method of assisting visual exploration for individuals suffering from a retinal condition resulting in a scotoma and, more particularly, a method S for assisting visual exploration by such an individual of a digital image on a display device, the method including: —recognizing, using shape recognition software, at least one object contained in an object area of the digital image, —determining a blind area in the image, corresponding to a position of the scotoma in the field of vision of the user looking at the image, —if the blind area and the object area are detected to be in close proximity to each other, applying image processing to the image consisting in highlighting the object area for the user.

公开(公告)号：US20170227532A1

公开(公告)日：2017-08-10

申请号：US15501714

申请日：2015-08-03

Applicant: BIOMERIEUX ,  UNIVERSITE D'AIX MARSEILLE ,  CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE

Inventor： Laure ALLARD ,  Thomas TRIMAILLE

IPC: G01N33/543 ,  G01N33/545 ,  G01N33/531

CPC classification number: G01N33/5432 ,  B82Y5/00 ,  G01N33/531 ,  G01N33/54353 ,  G01N33/54393 ,  G01N33/545 ,  G01N33/586

Abstract: The invention provides a novel method of preparing a capture phase for detecting and/or quantifying a target biological entity, said capture phase including a biological ligand for the biological entity, said biological ligand being covalently bonded to an amphiphilic polymer and being immobilized on a solid support, the method being characterized in that the biological ligand is immobilized on the solid support by bringing the solid support into contact with a dispersion of micelles formed by a plurality of chains of the amphiphilic polymer, said micelles carrying a plurality of molecules of the biological ligand on the surface thereof. The invention also provides corresponding capture phases and associated detection methods and kits.

公开(公告)号：US09701962B2

公开(公告)日：2017-07-11

申请号：US14895277

申请日：2014-06-05

Applicant: Institut National de la Sante et de la Recherche Medicale (INSERM) ,  Universite de Bordeaux ,  Universite d'Aix-Marseille ,  Institut Jean Paoli & Irene Calmettes ,  Centre National de la Recherche Scientifique

Inventor： Philippe Barthelemy ,  Khalid Oumzil ,  Palma Rocchi ,  Julie Acunzo

IPC: A01N43/04 ,  A61K31/70 ,  C12N15/113 ,  A61K9/107 ,  C12N15/11 ,  A61K47/48 ,  A61K45/06 ,  A61K31/712 ,  A61K31/713 ,  A61K31/7088

CPC classification number: C12N15/113 ,  A61K9/1075 ,  A61K31/7088 ,  A61K31/712 ,  A61K31/713 ,  A61K45/06 ,  A61K47/543 ,  C12N15/111 ,  C12N2310/11 ,  C12N2310/31 ,  C12N2310/315 ,  C12N2310/3231 ,  C12N2310/3515 ,  C12N2320/30 ,  C12N2320/31 ,  C12N2330/30

Abstract: The present invention concerns an oligonucleotide modified by substitution at the 3′ or the 5′ end by a moiety comprising at least one ketal functional group, wherein the ketal carbon of said ketal functional group bears two saturated or unsaturated, linear or branched, hydrocarbon chains comprising from 1 to 22 carbon atoms, and the use therefore as a medicament, in particular for use for treating cancer.

公开(公告)号：US20170183620A1

公开(公告)日：2017-06-29

申请号：US15304887

申请日：2015-04-21

Applicant: FONDATION MEDITERRANEE INFECTION ,  UNIVERSITE D'AIX MARSEILLE ,  CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) ,  INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE)

Inventor： Didier RAOULT ,  Saber KHELAIFIA ,  Michel DRANCOURT

IPC: C12N1/20 ,  C12N1/38

CPC classification number: C12P5/023 ,  C12N1/20 ,  C12N1/38 ,  C12P39/00 ,  Y02E50/343

Abstract: The present invention relates to a method for cultivating in vitro in an acellular culture medium, bacteria for which the growth is sensitive to oxygen content, said bacterium being selected from anaerobic bacteria and intracellular micro-aerophilic bacteria, characterized in that uric acid is added into said acellular culture medium, and said bacterium is cultivated in said culture medium in the presence of oxygen.

公开(公告)号：US20170073383A1

公开(公告)日：2017-03-16

申请号：US15125237

申请日：2015-03-10

Applicant: Universite D'Aix-Marseille

Inventor： Jacques Fantini ,  Nouara Yahi

IPC: C07K14/47

CPC classification number: C07K14/4711 ,  A61K38/00 ,  C07K14/47 ,  Y02A50/471

Abstract: The invention relates to a chimeric peptide displaying the ganglioside-binding properties of both α-synuclein and β-amyloid peptide. Such peptide is useful in preventing or treating any condition which involves gangliosides as cell surface receptor sites, including neurodegenerative disorders, infectious diseases, or tumors.

Abstract translation: 本发明涉及显示α-突触核蛋白和β-淀粉样蛋白肽的神经节苷脂结合特性的嵌合肽。 这样的肽可用于预防或治疗任何涉及神经节苷脂作为细胞表面受体位点的病症，包括神经变性疾病，感染性疾病或肿瘤。

公开(公告)号：US20160264666A1

公开(公告)日：2016-09-15

申请号：US15165152

申请日：2016-05-26

Applicant: INSERM (Institut National de la Sante et de la Recherche Medicale) ,  INSTITUT JEAN PAOLI & IRENE CALMETTES ,  UNIVERSITE D'AIX-MARSEILLE ,  Universite Claude Bernard - Lyon 1 ,  Centre Leon Berard

Inventor： Julien Faget ,  Christophe Caux ,  Christine Menetrier-Caux ,  Jacques Nunes ,  Daniel Olive

IPC: C07K16/28 ,  G01N33/574

CPC classification number: C07K16/2818 ,  A61K2039/505 ,  C07K16/28 ,  C07K2317/565 ,  C07K2317/75 ,  C07K2317/76 ,  C07K2317/92 ,  G01N33/56972 ,  G01N33/57415

Abstract: The present invention provides antibodies directed against ICOS or a derivative thereof which neutralize ICOS engagement on Treg by inhibiting the fixation between ICOS and ICOS-L and abrogate proliferation of Treg induced by plasmacytoid dendritic cells. The present invention further provides antibodies directed against ICOS or a derivative thereof which induce IL-10 and IFNγ production, induce CD4+ T cells proliferation, reduce Tconv proliferation, and increase the immunosuppressive function of Treg.

Abstract translation: 本发明提供针对ICOS或其衍生物的抗体，其通过抑制ICOS和ICOS-L之间的固定并消除由浆细胞样树突状细胞诱导的Treg的增殖来中和ICOS与Treg的结合。 本发明还提供了针对ICOS或其衍生物的抗体，其诱导IL-10和IFNγ产生，诱导CD4 + T细胞增殖，降低Tconv增殖，并增加Treg的免疫抑制功能。

公开(公告)号：US20160108398A1

公开(公告)日：2016-04-21

申请号：US14895277

申请日：2014-06-05

Applicant: INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) ,  UNIVERSITÉ DE BORDEAUX ,  UNIVERSITE D'AIX-MARSEILLE ,  INSTITUT JEAN PAOLI & IRENE CALMETTES ,  CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE

Inventor： Philippe Barthelemy ,  Khalid Oumzil ,  Palma Rocchi ,  Julie Acunzo

IPC: C12N15/113 ,  A61K45/06 ,  A61K31/713

CPC classification number: C12N15/113 ,  A61K9/1075 ,  A61K31/7088 ,  A61K31/712 ,  A61K31/713 ,  A61K45/06 ,  A61K47/543 ,  C12N15/111 ,  C12N2310/11 ,  C12N2310/31 ,  C12N2310/315 ,  C12N2310/3231 ,  C12N2310/3515 ,  C12N2320/30 ,  C12N2320/31 ,  C12N2330/30

Abstract: The present invention concerns an oligonucleotide modified by substitution at the 3′ or the 5′ end by a moiety comprising at least one ketal functional group, wherein the ketal carbon of said ketal functional group bears two saturated or unsaturated, linear or branched, hydrocarbon chains comprising from 1 to 22 carbon atoms, and the use therefore as a medicament, in particular for use for treating cancer.

Abstract translation: 本发明涉及通过在3'或5'末端被包含至少一个缩酮官能团的部分取代而修饰的寡核苷酸，其中所述缩酮官能团的缩酮碳具有两个饱和或不饱和的直链或支链烃链 其包含1至22个碳原子，因此用作药物，特别是用于治疗癌症。